

**ASX ANNOUNCEMENT****21 November 2022****Final clinical trial participant completes study**

---

**21 November 2022** – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced today that the final participant enrolled into Cann Group’s Phase III low-dose CBD clinical trial has attended their last study visit, and data entry for the trial has been completed. A total of 257 participants have completed the trial, exceeding the Company’s initial target of 212.

Study results are anticipated to be finalised early in the 2023 calendar year, shortly after which Cann expects to submit its formal drug registration application to the Therapeutic Goods Administration (TGA).

The clinical trial is investigating the safety and efficacy of Cann’s proprietary Satipharm CBD capsules for treating sleep disturbance. This forms part of the Company’s strategy to register a low-dose CBD medicine for over-the-counter sale, making it available to consumers at pharmacies without requiring a prescription.

On 6 April 2022 global healthcare company, GSK Consumer Healthcare (trading as Haleon), secured an exclusive evaluation and option agreement with Cann for the marketing and sale of over-the-counter Satipharm CBD capsules for Australia and potentially other markets globally. The parties subsequently agreed to and signed a non-binding commercial term sheet on 7 November 2022.

Cann Group’s CEO, Peter Crock, said, “This is a great achievement as part of our over-the-counter CBD strategy, and shows how quickly we are working towards a definitive outcome. We look forward to updating our investors on the results of this study in the coming weeks.”

**Authorised for release by Deborah Ambrosini, Company Secretary, Cann Group Limited.**

**For all media enquiries please contact:**

Rhys Cohen  
Senior Corporate Communications Manager  
+61 449 679 095  
[rhys.cohen@canngrouponlimited.com](mailto:rhys.cohen@canngrouponlimited.com)

**For all other information please contact:**

Peter Crock  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Deborah Ambrosini  
CFO & Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[deborah.ambrosini@canngrouponlimited.com](mailto:deborah.ambrosini@canngrouponlimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

**Learn more at:** [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)